Novo Nordisk plans to eliminate approximately 250 jobs in the U.S., according to a spokesman from the company, as well as add an undetermined number of staff to newly created positions.
 
Novo Nordisk employs more than 42,000 people in 79 countries. The company, a specialist in diabetes, has seen more modest growth in recent years as a result of pricing pressures in the U.S., which accounts for approximately half of its revenue. Annual revenues were flat at $17.9 billion in 2017, and earnings were up just 1%. According to the spokesman, Novo Nordisk will pay higher rebates for U.S. Medicare in 2019.
 
One hundred of the planned staff reductions are from back-office positions in the company’s U.S. headquarters in Princeton, NJ, and the remaining 150 are among diabetes treatment support positions. 
 
The company previously announced plans to cut 400 staff in Denmark and China as part of an effort to focus on investments in biologics and technology innovation.